Prognostic Value of Surem TRAF3IP2 Level in Patients With Acute Myocardial Infarction

Launched by NANJING MEDICAL UNIVERSITY · Sep 8, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the levels of a specific protein called surem TRAF3IP2 in patients who have experienced an acute myocardial infarction, which is commonly known as a heart attack. The main goal is to see if measuring this protein can help predict how well patients will do after their heart attack. The trial is currently looking for participants, and it is open to both men and women between the ages of 65 and 74.

To be eligible for the study, participants must have had a heart attack and undergone a procedure called coronary angiography, which looks at the blood vessels of the heart. They should also have received treatment within 72 hours of being admitted to the hospital. However, the study will not include individuals who have severe heart failure, active cancers, serious infections, thyroid problems, a life expectancy of less than one year, or those who are not suitable for a procedure called PCI, which helps open blocked arteries. If you decide to take part in this trial, you’ll help researchers understand more about heart health and potentially improve care for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with acute myocardial infarction
• • 2. patients received coronary angiography
• • 3. invasive management within 72 h of hospital admission
• Exclusion Criteria:
• • 1. NYHA III-IV
• • 2. malignant tumor
• • 3. acute infection
• • 4. thyroid dysfunction
• • 5. Life expectancy of b1 y
• • 6. Unsuitable for PCI